Zymeworks Inc. (ZA8.F)
| Previous close | 7.65 |
| Open | 8.00 |
| Bid | 8.05 x N/A |
| Ask | 8.35 x N/A |
| Day's range | 8.00 - 8.00 |
| 52-week range | 5.78 - 11.69 |
| Volume | |
| Avg. volume | 16 |
| Market cap | 605.39M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference: Zymeworks’ management will participate in one-on-one meetings on May 15th in Las
Simply Wall St.We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results a
